DGAP-News

MOLOGEN AG: New strategy and major study milestones achieved in first six months of 2016

DGAP-News: MOLOGEN AG / Key word(s): Half Year Results
MOLOGEN AG: New strategy and major study milestones achieved in first six
months of 2016

11.08.2016 / 07:23
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR
INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER
JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

Press release N 13 / 2016 dated August 11, 2016

MOLOGEN AG: New strategy and major study milestones achieved in first six
months of 2016

- Start of implementation of new "Next Level" strategy

- Forecast for full year 2016 unchanged

- Start of combination study with lead product lefitolimod (MGN1703) and
checkpoint inhibitor Yervoy(R) in collaboration with MD Anderson Cancer
Center

- Extension of TEACH study following good results in initial study phase


Berlin, August 11, 2016 - The biotech company MOLOGEN (ISIN DE0006637200;
Frankfurt Stock Exchange Prime Standard: MGN) conducted and completed a
portfolio review in the first half of 2016. The company has already started
to implement its new "Next Level" strategy as well as the associated
virtualization and stronger focus of the company. At the Annual General
Meeting taking place today in Berlin, MOLOGEN will present the company's
new strategic direction. The forecast for the current financial year
remains unchanged.

Additionally, major milestones were achieved in two of the clinical trials
with the lead drug candidate lefitolimod (MGN1703) in the first six months
of the year. With the enrollment of the first patients the first
combination study (phase I study) started in July 2016:
lefitolimod (MGN1703) and the checkpoint inhibitor ipilimumab (Yervoy(R)).
Moreover, following positive study results from the initial phase, the
extension phase of the TEACH study (indication HIV) including more patients
and a longer treatment period started in June.

Implementation of new "Next Level" strategy commences

In the first half of the current financial year MOLOGEN dealt in-depth with
the review of its existing product pipeline. The new "Next Level" corporate
strategy was devised on the basis of the findings of this portfolio review.
In future, MOLOGEN will concentrate on the further development of its most
advanced lead product, the immunotherapy lefitolimod (MGN1703), as well as
its next-generation molecules EnanDIM(R). MOLOGEN has commissioned a